Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Revvity Inc (RVTY) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Revvity Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.24, while Revvity Inc trades at $110.72 (market cap $12.42B). The key difference: Revvity Inc pays a 0.25% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Revvity Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPIRVTY
Sector
Income / Options OverlayTechnology
52-Week High
$49.54$117.75
52-Week Low
$38.13$82.26
Market Cap
$12.42B
Enterprise Value
$14.91B
Dividend Yield
0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.40, down 2.45% over the past day, with technical indicators signaling a bearish trend. The ETF generates a high yield through weekly covered call distributions, but its concentrated tech holdings and call-writing strategy cap upside potential while exposing investors to net asset value erosion during market downturns. Recent news highlights its 25% yield appeal but cautions on structural limitations.

Outlook remains cautious due to the ETF's high-risk income strategy; opportunities exist for yield-seeking investors comfortable with capped gains and volatility, but risks include underperformance versus benchmarks and NAV decay in declining markets. Investor sentiment is mixed, balancing high income against long-term growth constraints.

Revvity Inc

RVTY trades at $111.40, up 0.17% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company maintains stable revenue around $2.9B with an 8.26% net income margin, though its P/E ratio of 53.53 suggests premium valuation. Recent news highlights AI integration advances and FDA clearances, supporting growth initiatives.

Outlook is cautiously optimistic with strong analyst buy ratings (51.72%) and a $111.43 consensus target, but high valuation and margin pressures pose risks. Earnings on August 4, 2026, will be critical for confirming growth trajectory amid competitive and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY